PMID- 33900820
OWN - NLM
STAT- MEDLINE
DCOM- 20220103
LR  - 20220103
IS  - 2167-9436 (Electronic)
IS  - 2167-9436 (Linking)
VI  - 40
IP  - 2
DP  - 2021 Apr
TI  - Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies 
      for Cancer Immunotherapy: Still a Long Way to Go.
PG  - 81-85
LID - 10.1089/mab.2021.0003 [doi]
AB  - Antibody-based cancer immunotherapy has revolutionized oncology. The first 
      successful therapeutic antibodies relied on eliciting immune-mediated 
      cytotoxicity (rituximab) or modulation of intracellular signaling (trastuzumab). 
      Further attempts to enhance the antitumor effects led to the development of 
      immunoconjugates with radioactive or cytotoxic compounds (tositumomab, 
      brentuximab vedotin). Another line of research led to the bispecific antibodies 
      that can enhance the formation of immunological synapse between cancer and 
      cytotoxic T cells (blinatumomab). Despite the constant advances in design and 
      production, the application of monoclonal antibodies in cancer treatment remains 
      limited by the presence of specific cell surface markers. A rational approach to 
      target intracellular cancer antigens was proposed almost two decades ago by the 
      development of anti-peptide human leukocyte antigen (HLA) complex (T cell 
      receptor-like/mimic) antibodies. They could recognize specifically cancer 
      neoantigens expressed in the context of specific HLA molecules theoretically 
      providing unprecedented specificity. Furthermore, they can be developed in a 
      semigeneric format, that is, to target common neoantigens expressed in the 
      context of common HLA molecules. It is rationale to expect that the development 
      of such antibodies in the format of bispecific antibody constructs can bring 
      together the power of specific antibody-based recognition and that of T 
      cell-mediated lysis. There are already some preliminary reports that suggest such 
      constructs would be an achievable goal. In this brief review, we discuss some of 
      the successful preclinical developments in the field and the major challenges 
      that are yet to be addressed.
FAU - Shivarov, Velizar
AU  - Shivarov V
AD  - Department of Genetics, Faculty of Biology, St. Kliment Ohridski Sofia 
      University, Sofia, Bulgaria.
AD  - Medical Department, PRAHS, Sofia, Bulgaria.
FAU - Blazhev, Georgi
AU  - Blazhev G
AD  - Department of Genetics, Faculty of Biology, St. Kliment Ohridski Sofia 
      University, Sofia, Bulgaria.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Monoclon Antib Immunodiagn Immunother
JT  - Monoclonal antibodies in immunodiagnosis and immunotherapy
JID - 101590955
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Immunoconjugates)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Antibodies, Bispecific/immunology/*therapeutic use
MH  - Antibodies, Monoclonal/immunology/therapeutic use
MH  - Antineoplastic Agents, Immunological/therapeutic use
MH  - Cytotoxicity, Immunologic/immunology
MH  - Humans
MH  - Immunoconjugates/therapeutic use
MH  - Immunotherapy/*trends
MH  - Neoplasms/immunology/*therapy
MH  - Receptors, Antigen, T-Cell/immunology/*therapeutic use
OTO - NOTNLM
OT  - TCR mimic antibodies
OT  - bispecific antibodies
OT  - cancer
OT  - immunotherapy
EDAT- 2021/04/27 06:00
MHDA- 2022/01/04 06:00
CRDT- 2021/04/26 17:12
PHST- 2021/04/26 17:12 [entrez]
PHST- 2021/04/27 06:00 [pubmed]
PHST- 2022/01/04 06:00 [medline]
AID - 10.1089/mab.2021.0003 [doi]
PST - ppublish
SO  - Monoclon Antib Immunodiagn Immunother. 2021 Apr;40(2):81-85. doi: 
      10.1089/mab.2021.0003.